Mechanistically, the anti-cancer effect of metformin was achieved by inhibiting the UFMylation of SLC7A11, a cysteine transporter critical for ferroptosis, implying that targeting the UFM1/SLC7A11 pathway could be a promising cancer treatment strategy. This evidence concerns the gene UFM1 and cancer.